Skip to contentA
Aquestive Therapeutics, Inc.
A
AQSTAquestive Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$8.72M$8.72M−27.7% vs Q1 2024 Net Income-$22.93M-$22.93MN/M vs Q1 2024 EPS Diluted-$0.24-$0.24N/M vs Q1 2024 Operating Income-$19,365,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aquestive Therapeutics, Inc. · CIK 1398733 · Engraved from SEC EDGAR
Free Cash Flowderived-$23,535,000N/M Margins · derivedOperating margin-222.1%−147.8 pt vs Q1 2024
Net margin-263.0%−156.5 pt vs Q1 2024
ended Mar 31, 2025 · filed May 12, 2025 · 42 d after period end